Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial-Reference-Cited by-同舟云学术

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial

Published:2013-06-11 Issue:11 Volume:15 Page:1040-1048
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Hermansen K.¹,Bækdal T. A.²,Düring M.²,Pietraszek A.¹,Mortensen L. S.¹,Jørgensen H.³,Flint A.²

Affiliation:

1. Department of Medicine and Endocrinology MEA Aarhus University Hospital Aarhus Denmark

2. Novo Nordisk A/S Søborg Denmark

3. Department of Animal Science Aarhus University Foulum Tjele Denmark

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12133

Reference44 articles.

1. Diabetic dyslipidaemia: from basic research to clinical practice*

2. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

3. Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women

4. Postprandial lipoprotein metabolism and atherosclerosis

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments;International Journal of Molecular Sciences;2023-09-11

2. The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9;Heliyon;2023-09

3. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice;European Journal of Pharmacology;2023-09

4. Incretins and cardiovascular disease: to the heart of type 2 diabetes?;Diabetologia;2023-08-05

5. Meta-Inflammation and New Anti-Diabetic Drugs: A New Chance to Knock Down Residual Cardiovascular Risk;International Journal of Molecular Sciences;2023-05-12